Product Name: Human Complement C5 Antibody (Ravulizumab, Research Use)
Catalog Number: NBR-0608
Target Name: Complement C5
Trade Name: Ravulizumab
Antibody Drug Description: Ravulizumab, a humanized monoclonal antibody, is a complement C5 inhibitor developed by Alexion Pharmaceuticals for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS). Appearance: Transparent Liquid
Molecular Weight: ~150kDa
CAS：N/A
Solubility: Water; PBS, TBS Buffer etc.
Expression System: CHO Expressed
Isotype of Ab: Ab. Isotype - IgG

  Gene Name: Complement C5
Synonyms: CPAMD4 ; C5; C5a
Target Description: C5 (Complement C5) is a Protein Coding gene. Diseases associated with C5 include Complement Component 5 Deficiency and Eculizumab, Poor Response To. Among its related pathways are Complement cascade and Immune response Lectin induced complement pathway. Gene Ontology (GO) annotations related to this gene include signaling receptor binding and endopeptidase inhibitor activity. An important paralog of this gene is C3.
Ensembl: ENSG00000106804
Uniprot:  P01031